Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.
Recent advances in cancer immunology have increased our understanding of the mechanisms that cancer cells use to either avoid detection by or to de-activate the immune system. Novel immuno-oncology drugs are designed specifically to block immune suppression induced by tumors, or to actively initiate and augment an immune response against tumors. Harnessing the body’s immune system has the potential to eliminate tumors and prevent their recurrence.
Apexigen’s Immuno-oncology Strategy
Apexigen is focused on discovering and developing innovative drugs that enhance tumor-specific immunity. The use of its APXiMAB™ platform enables Apexigen to discover antibodies with unique attributes against known and novel immune system targets. These antibodies have demonstrated the potential to become the next generation of cancer therapies as we work toward a cure for cancer.
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting